- Home
- NYMT vs VERV Comparison
NYMT vs VERV Comparison
Compare NYMT & VERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NYMT
- VERV
- Stock Information
- Founded
- NYMT 2003
- VERV 2018
- Country
- NYMT United States
- VERV United States
- Employees
- NYMT N/A
- VERV N/A
- Industry
- NYMT Real Estate Investment Trusts
- VERV Medicinal Chemicals and Botanical Products
- Sector
- NYMT Real Estate
- VERV Health Care
- Exchange
- NYMT Nasdaq
- VERV Nasdaq
- Market Cap
- NYMT 569.3M
- VERV 601.2M
- IPO Year
- NYMT 2004
- VERV 2021
- Fundamental
- Price
- NYMT $6.38
- VERV $5.60
- Analyst Decision
- NYMT Buy
- VERV Strong Buy
- Analyst Count
- NYMT 4
- VERV 5
- Target Price
- NYMT $8.00
- VERV $25.20
- AVG Volume (30 Days)
- NYMT 332.9K
- VERV 1.7M
- Earning Date
- NYMT 10-30-2024
- VERV 08-08-2024
- Dividend Yield
- NYMT 12.54%
- VERV N/A
- EPS Growth
- NYMT N/A
- VERV N/A
- EPS
- NYMT N/A
- VERV N/A
- Revenue
- NYMT $151,991,000.00
- VERV $20,648,000.00
- Revenue This Year
- NYMT N/A
- VERV $57.08
- Revenue Next Year
- NYMT $31.44
- VERV N/A
- P/E Ratio
- NYMT N/A
- VERV N/A
- Revenue Growth
- NYMT 206.18
- VERV 279.70
- 52 Week Low
- NYMT $5.51
- VERV $4.31
- 52 Week High
- NYMT $9.68
- VERV $20.12
- Technical
- Relative Strength Index (RSI)
- NYMT 47.63
- VERV 48.86
- Support Level
- NYMT $6.27
- VERV $4.72
- Resistance Level
- NYMT $6.72
- VERV $6.34
- Average True Range (ATR)
- NYMT 0.13
- VERV 0.49
- MACD
- NYMT -0.02
- VERV 0.10
- Stochastic Oscillator
- NYMT 20.00
- VERV 48.04
About NYMT New York Mortgage Trust Inc.
New York Mortgage Trust Inc is a real estate investment trust for federal income tax purposes, in the business of acquiring, investing in, financing and managing mortgage-related and residential housing-related assets. The company's investment portfolio consists of Structured multi-family property investments such as multi-family CMBS an preferred equity in, and mezzanine loans to owners of multi-family properties. Distressed residential assets such as residential mortgage loans sourced from distressed markets and non-Agency RMBS. Second mortgages, Agency RMBS, and certain other mortgage-related and residential housing-related assets.
About VERV Verve Therapeutics Inc.
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.